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Abstract
Background: Mutations of an alternative splice donor site located within the gag region has previously been shown to broaden
the pathogenic potential of the T-lymphomagenic gammaretrovirus Moloney murine leukemia virus, while the equivalent
mutations in the erythroleukemia inducing Friend murine leukemia virus seem to have no influence on the disease-inducing
potential of this virus. In the present study we investigate the splice pattern as well as the possible effects of mutating the
alternative splice sites on the oncogenic properties of the B-lymphomagenic Akv murine leukemia virus.
Results: By exon-trapping procedures we have identified a novel gammaretroviral exon, resulting from usage of alternative
splice acceptor (SA') and splice donor (SD') sites located in the capsid region of gag of the B-cell lymphomagenic Akv murine
leukemia virus. To analyze possible effects in vivo of this novel exon, three different alternative splice site mutant viruses, mutated
in either the SA', in the SD', or in both sites, respectively, were constructed and injected into newborn inbred NMRI mice. Most
of the infected mice (about 90%) developed hematopoietic neoplasms within 250 days, and histological examination of the
tumors showed that the introduced synonymous gag mutations have a significant influence on the phenotype of the induced
tumors, changing the distribution of the different types as well as generating tumors of additional specificities such as de novo
diffuse large B cell lymphoma (DLBCL) and histiocytic sarcoma. Interestingly, a broader spectrum of diagnoses was made from
the two single splice-site mutants than from as well the wild-type as the double splice-site mutant. Both single- and double-
spliced transcripts are produced in vivo using the SA' and/or the SD' sites, but the mechanisms underlying the observed effects
on oncogenesis remain to be clarified. Likewise, analyses of provirus integration sites in tumor tissues, which identified 111 novel
RISs (retroviral integration sites) and 35 novel CISs (common integration sites), did not clearly point to specific target genes or
pathways to be associated with specific tumor diagnoses or individual viral mutants.
Conclusion: We present here the first example of a doubly spliced transcript within the group of gammaretroviruses, and we
show that mutation of the alternative splice sites that define this novel RNA product change the oncogenic potential of Akv
murine leukemia virus.
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Background
Many murine leukemia viruses (MLVs) belonging to the
genus gammaretroviruses induce cancer when injected
into susceptible newborn mice [1,2]. These simple retro-
viruses do not themselves harbor transduced oncogenes,
and their ability to cause cancer relies on the host cellular
genes that are transcriptionally activated or otherwise
mutated as a result of the integrated provirus [3-6].
Regarding the virus itself, it is well documented that the
LTR region plays a crucial role for both the strength and
cell type specificity of disease induction [7,8]. Within the
LTR the specificity has been located mainly to the
enhancer region in U3, and further narrowed down to the
sequences defining different transcription factor binding
sites [9-12]. In spite of this predominant role of the LTR in
MLV pathogenesis, also sequences outside this region
have been shown to be important for the ability and
potency of a particular virus to induce cancer. Infection is
mediated by interaction between the viral envelope pro-
tein (Env) and a specific host cell receptor, and for the eco-
tropic MLVs such as Moloney, Akv, and SL3-3, this
receptor has been identified as the mouse cationic amino
acid transporter 1 (mCAT1) [13,14]. A significant role of
env in MLV pathogenesis is the involvement in the gener-
ation of recombinant polytropic viruses that takes place
during T-cell lymphoma development. These MCF (mink
cell focus-forming) viruses have the ability to superinfect
cells, an aspect which is thought to contribute to tumor
formation [15,16]. In addition to the env gene, and per-
haps somewhat surprisingly, the viral gag gene sequences
have also proven to play a role in MLV pathogenesis.
Thus, Audit et al. (1999) [17] showed that the introduc-
tion of only three synonymous nucleotide mutations in
the capsid-coding gene of Moloney MLV (Mo-MLV)
changed the oncogenic properties of this virus. The muta-
tions were located at an alternative splice donor site (SD'),
which together with the canonical env splice acceptor site
was shown to produce a subgenomic transcript of 4.4 kb
[18]. The equivalent transcript, produced by Friend MLV,
was subsequently shown to be packaged into virions,
reversely transcribed and integrated in the host genome by
normal viral mechanisms [19]. While wild-type Mo-MLV
induces T-cell lymphomas in 100% of the inoculated
mice, the SD' mutant virus exhibited a much broader spe-
cificity, thus inducing – besides the expected T-cell tumors
– erythroid or myelomonocytic leukemias. In contrast, the
corresponding mutations in a Friend MLV background
did not seem to influence the pathogenic potential of this
virus at all. Both wild-type and mutant Friend MLVs
induced exclusively the characteristic erythroleukemia
[17]. So it seems that the importance for the disease-
inducing potential of the SD' site, although conserved
among many species, is strongly dependent on the virus
type.
The SD' site has also been found to be used for production
of the oncogenic gag-myb fusion RNAs in promonocytic
leukemias induced by Mo-MLV in pristane-treated BALB/
c mice [20]. When the SD' site was mutated in this model,
the overall disease incidence was not affected; however
the proportion of myeloid leukemia decreased signifi-
cantly, while the proportion of lymphoid leukemia
increased. Moreover, no 5' insertional activation of c-myb
(using alternative splice donor sites) could be found,
thereby signifying a specific requirement of the SD' site for
this mechanism [21].
Here we report of the identification of an alternative splice
acceptor site, SA', located in the capsid region of gag,
which together with the gag splice donor site, SD' (corre-
sponding to the one reported for Moloney and Friend
MLV), or together with a second alternative gag  splice
donor site, SD*, defines a novel exon within the genus
gammaretroviruses. We show that RNA splicing by use of
the alternative splice sites does indeed take place in tumor
tissue, and that both double- and single-spliced tran-
scripts are produced. When mutating the SD', the SA', or
both sites simultaneously, the splicing pattern is affected
in a predictable way. Moreover, we demonstrate that the
SA' and SD' mutations alter the oncogenic specificity of
the Akv MLV, displayed by a change in the distribution of
the diagnoses of the resulting tumors as well as by an
induction of tumors of altered specificity such as histio-
cytic sarcoma and de novo diffuse large B cell lymphoma
(DLBCL).
Results
Identification of a novel exon residing within the gag 
region of Akv MLV
In order to identify potential alternative splice donor and
splice acceptor sites in Akv MLV, exon-trapping was per-
formed using the exon-trapping vector pSPL3 (see Materi-
als and Methods). In short, an exon resulting from usage
of the alternative splice acceptor (SA') and either one of
two alternative splice donor (SD' or SD*) sites located in
the capsid region of gag (Fig. 1), was isolated and verified
by RT-PCR analyses of RNA isolated from Akv MLV
infected cells (data not shown). The size of the exon is 235
bp or 180 bp, depending on the splice donor site used.
Mutations of the alternative splice sites affect the 
specificity of the induced tumors
To analyze a possible effect in vivo of the novel exon,
defined by SA' and SD', three different alternative splice
site mutant viruses, Akv-CD, Akv-EH, and Akv-CDH,
mutated in either the SA' or SD' site, or in both sites simul-
taneously, were constructed and injected into newborn
mice of the inbred NMRI strain. Fig. 1 shows the precise
locations of the synonymous mutations around the
trapped exon. Without altering the coding potential of theRetrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
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capsid gene, the mutations affect the branch point site, the
pyrimidine region, the conserved splice junction AG and
GT dinucleotides, and the fairly well-conserved exonal A
at the SD' junction site. The positions of the three intron
mutations at the SD' junction site are identical to those in
Moloney and Friend MLV described by Audit et al. (1999)
[17].
As can be seen from Fig. 2 and Table 1 the majority of the
infected mice (about 90%) developed tumors within 250
days with similar average latency periods of about 200
days for the four types of virus. Histological examination
(examples shown in Fig. 3) and diagnosis according to the
Bethesda classification [22] revealed that a large propor-
tion (approx. 70%) of the total numbers of tumors could
be classified as either follicular B-cell lymphoma (FBL)
(13%), diffuse large B-cell lymphoma (DLBCL) pro-
gressed from FBL (33%), or plasmacytoma (PCT) (25%)
(Table 2). However, the distribution was quite different
within the different virus series; thus, almost one quarter
of the Akv-wt induced tumors were diagnosed as FBL,
while no tumor of the Akv-CD group (p < 0.05) or one
tumor each of the Akv-EH or Akv-CDH groups fell into
this group. In contrast, within the DLBCL tumors pro-
gressed from FBL the frequencies are similar (ranging
from 24% to 39%) no matter if the causative virus con-
tained mutated SA' and/or SD' sites or not. In the PCT
group it appears that mutating the SA' site significantly
impaired the ability of the virus to induce PCT (p < 0.05).
On the other hand, this effect was not statistically signifi-
cant if the SD' site was mutated, and curiously if both sites
were mutated, wild-type level for PCT induction was
restored.
In line with this, the most dramatic effect in general was
seen when only the SA' site was mutated as shown for Akv-
CD; the tumor incidence of this mutant with respect to
splenic marginal zone lymphoma (SMZL) increased from
Location of the trapped exon Figure 1
Location of the trapped exon. Upper panel shows the structure of proviral Akv MLV DNA with the positions of the splice sites 
indicated (SD; splice donor, SA; splice acceptor). Arrows signify the PCR primers used to verify the stability of the introduced 
mutations. Lower panel shows the positions and types of the introduced mutations, marked by asterisks and underlined. The 
SA'/SD'-delineated exon is indicated by the box. The boldfaced A in the sequence indicates the presumed branch point.
SD-env
[686]
SD’-gag
[2092]
SA’-gag 
[1856]
SA-env
[5985]
LTR
CCAGCGATCTATATAACTGGAAAAATAATAATCCATCATTCAGTGAA GAT-----------AAAGAG GTAGGAA
CCTCTGATCTATATAACTGGAAAAATAATAATCCTTCCTTCTCTGAG GAT-----------AAAGAG GTAGGAA
CCTCTGATCTATATAACTGGAAAAATAATAATCCTTCCTTCTCTGAG GAT-----------AAAGGG GACGAAA
CCAGCGATCTATATAACTGGAAAAATAATAATCCATCATTCAGTGAA GAT-----------AAAGGG GACGAAA
Akv-wt
Akv-CD
Akv-EH
Akv-CDH
SD*-gag
[2038]
LTR
2092 1856 1810
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8% to 28% (p < 0.1) and decreased to 0% as shown for
Akv-EH (p < 0.05) and for Akv-CDH (p = 0.5). Moreover,
the Akv-CD mutant virus was the only one that displayed
a capability for inducing histiocytic sarcoma, a tumor type
which has not been observed in any of our previous stud-
ies using NMRI mice (inbred or random-bred) infected
with Akv, SL3-3, or different derived mutants of these. So
in brief, synonymous mutations at the SA' site of Akv MLV
markedly altered the oncogenic potential of the virus by
significantly impairing the ability to induce both FBL and
PCT. Besides, while the development of SMZL was
increased by Akv-CD, it was abolished in Akv-EH and Akv-
CDH, and most notably, a novel potential for inducing
histiocytic sarcoma was established.
The most pronounced effect of mutating the SD' site (Akv-
EH) is the frequent occurrence (35%) of diffuse tumors,
which according to the Bethesda classification represent
DLBCL centroblastic (more than 50% of the infiltrating
population is centroblasts). These tumors, where progres-
sion is not from either a follicular or a marginal lym-
phoma, are comparable to the de novo lymphomas in
humans, and to emphasize this association we have used
the term de novo DLBCL (Table 2). Strikingly, de novo DLB-
CLs were never observed among the wild-type induced
tumors or among the other mutant induced tumors (p <
0.05). The finding of such tumors in mice is rare and
could be exploited to understand the molecular changes
in de novo DLBCL of mice, and eventually a useful mouse
model of human de novo DLBCL might be generated from
this set-up.
Quite unexpectedly, the effect of mutating the SA' and SD'
sites simultaneously (Akv-CDH) was the less manifested
one. FBL incidence dropped from 23% to 7%; otherwise
this mutant in our experimental setting displayed similar
tumorigenic potential as the wild-type Akv MLV.
Conservation of the introduced splice site mutations in the 
tumors
To determine the stability of the introduced mutations,
the regions containing the mutations were PCR amplified
Table 1: Disease latency and frequency
Virus Average latency period (days) Frequency of mice developing hematopoitic tumors
Akv-wt 184 ± 26 40/40
Akv-CD 201 ± 30 17/19
Akv-EH 184 ± 34 17/18
Akv-CDH 190 ± 46 14/16
Pathogenicity of Akv and derived splice site mutants in inbred NMRI mice Figure 2
Pathogenicity of Akv and derived splice site mutants in inbred NMRI mice. Shown are the cumulative incidences of tumor 
development related to age of injected mice (in days).
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Histopathology of tumors induced by Akv and derived splice site mutants Figure 3
Histopathology of tumors induced by Akv and derived splice site mutants. Representative examples are shown. (A to D) de 
novo diffuse large B-cell lymphoma. (A) Low magnification of a spleen infiltrated by a vaguely nodular lymphoid neoplasia (H&E 
staining). Magnification, ×25. (B) Higher magnification demonstrates that the neoplasia is composed of a monotonous popula-
tion of large cells with blastic chromatin, one to three nucleoli and abundant eosinophilic cytoplasm characteristic of centrob-
lasts (H&E staining). Magnification, ×640. (C) Anti-B220 highlights the large neoplastic cells, which are strongly positive 
(immunohistochemistry). Magnification, ×400. (D) Anti-CD3 shows that only few residual reactive T-cells are present (immu-
nohistochemistry). Magnification, ×400. (E to H) Follicular lymphoma. (E) Low magnification of a spleen infiltrated by a clear 
nodular lymphoid proliferation (H&E staining). Magnification, ×25 (F) Higher magnification shows a combination of large cen-
troblasts intermingled with small- to medium-sized lymphocytes or centrocytes (H&E staining). Magnification, ×640. (G) Anti-
B220 highlights the expansion of the follicles, mainly of the germinal center lymphoid cells (light brown) (immunohistochemis-
try). Magnification, ×25. (H) Anti-CD3 reveals the presence of abundant reactive T-cells intermingled with the neoplastic B-
cells (immunohistochemistry). Magnification, ×400. (I to L) Marginal zone cell lymphoma. (I) Low magnification of a spleen infil-
trated by a marginal zone lymphoma. Note that the follicles (F) are small and the cells surrounding these follicles expand and 
infiltrate the red pulp in a marginal zone pattern (H&E staining). Magnification, ×100. (J) Higher magnification showing that the 
neoplasia is composed of a monotonous population of small- to medium-sized cells with open fine chromatin, inconspicuous 
nucleoli and abundant light eosinophilic cytoplasm (H&E staining). Magnification, ×400. (K) Anti-CD79a reveals that the tumor 
cells in the marginal zone area are strongly positive, whereas the cells in the germinal centers (F) are weakly positive. The 
opposite staining pattern is seen with anti-B220 (data not shown) (immunohistochemistry). Magnification, ×200. (L) Higher 
magnification with anti-CD79a shows a uniform membranous positivity of the tumor cells (immunohistochemistry). Magnifica-
tion, ×400. (M to O) Histiocytic sarcoma. (M) Low magnification of a spleen diffusely infiltrated by a histiocytic sarcoma (H&E 
staining). Magnification, ×25. (N) Higher magnification shows the presence of large cells with abundant eosinophilic cytoplasm 
and bland nuclei characteristic of histiocytes (H&E staining). Magnification, ×400. (O) Anti-Mac 3 shows that all tumor cells are 
positive for this histiocytic marker, both in the cytoplasm and in the cell membrane (immunohistochemistry). Magnification, ×4 
Histopathological and immunohistological analyses of tumor tissues.Retrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
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from genomic DNA prepared from the induced tumors,
using the primers depicted in Fig. 1. The sequences of the
amplified fragments confirmed in all cases the integrity of
the introduced mutations (data not shown).
Both single- and double-spliced transcripts are generated 
in vivo
The observed effect of the mutated splice sites on the
oncogenic properties advocates that RNA splicing by
means of the alternative SA' and SD' sites does indeed take
place in vivo. To clarify and confirm the identity of the pro-
duced transcripts, the splice pattern in tumor tissues (and
for comparison in NIH 3T3 cells infected with the same
four viruses) was analyzed. RNA from the individual end-
stage tumors (or from virally infected cells) was isolated,
and conventional RT-PCRs were performed with primers
designed in such a way that it should be possible to iden-
tify all four potential splice products using 4 different
primer sets as shown in Fig. 4A.
With a few exceptions, all tumors were analyzed, and
sequences of the amplified RT-PCR products determined
to validate the specificity of the fragments (data not
shown). Representative results from each virus series are
shown in Fig. 4B. In all cases, PCR products representing
splice product A (the regular env transcript; primer set #4)
was observed, which implies that damage of the alterna-
tive splice sites, SA' and SD', does not impair the produc-
tion of the regular single-spliced env  RNA. Concerning
splice product D (primer set #1) it was never amplified,
neither from tumor tissues nor from cell culture studies,
strongly indicating that this is not a bona fide transcript.
The lack of detection of product D is unlikely to result
from a technical PCR-problem since the two primers have
been validated in other PCRs.
For the Akv wild-type induced tumors, RT-PCR products
representing the double-spliced product B (primer set #2),
and fragments of expected size amplified by primer set #3,
indicative of splice product B or C, were observed in all
cases. As would be expected primer set #2, which is
dependent on an intact SA' site, did not result in any
amplification products using RNA from Akv-CD or Akv-
CDH tumors. Surprisingly however, in five out of 14 ana-
lyzed Akv-EH tumor samples (represented by Akv-EH
tumor no. 14 in Fig. 4B), a product slightly smaller than
that of transcript version B was amplified. The subsequent
sequence analyses revealed that the alternative splice
donor site SD* (depicted in Fig. 1) in these cases consist-
ently had been used, resulting in the generation of a splice
product equivalent in structure to product B, however 54
nucleotides shorter. No correlation between tumor cell
specificity and usage of the SD* site could be observed,
since the five tumor samples originated from FBL, DLBCL
progressed from FBL, de novo DLBCL, and the single case
of STL (small T-cell lymphoma). The presence of the same
splice product from the SD* site was verified by sequence
analysis of RT-PCR products derived from tumors induced
by the wild-type virus in some cases, although the product
was consistently less prominent than product B.
Transcript C corresponds to the single-spliced transcript of
4.4 kb, which previously has been reported to be pro-
duced by both Friend and Moloney MLV using the SD'
together with the canonical env SA' site [18,19]. Our RT-
PCR results confirm the existence of this single-spliced
transcript, since products of the expected size were always
amplified with primer set #3 using RNA from Akv-CD
tumors (Fig. 4B), whereas product B (primer set #2) was
never amplified in this material.
In summary, by means of the alternative splice sites that
define the novel gag exon, both a single-spliced transcript
C as well as a novel double-spliced transcript B is pro-
duced in vivo, and when these alternative splice sites are
destroyed, the splicing pattern is changed concordantly.
Table 2: Frequency and latency of induced tumors
Virus FBL DLBCL
(progression
from FBL)
De novo
DLBCL#
PCT SMZL DLBCL
(progression
from SMZL)
SBL PTLL STL Histiocytic
sarcoma
Akv-wt 9/40 (23%) 13/40 (33%) 0/40 (0%) 13/40 (33%) 3/40 (8%) 0/40 (0%) 2/40 (5%) 0/40 (0%) 0/40 (0%) 0/40 (0%)
Akv-CD* 0/18 (0%) 7/18 (39%) 0/18 (0%) 1/18 (6%) 5/18 (28%) 1/18 (6%) 0/18 (0%) 0/18 (0%) 0/18 (0%) 4/18 (22%)
Akv-EH 1/17 (6%) 4/17 (24%) 6/17 (35%) 3/17 (18%) 0/17 (0%) 1/17 (6%) 0/17 (0%) 0/17 (0%) 1/17 (6%) 0/17 (0%)
Akv-CDH 1/14 (7%) 5/14 (36%) 0/14 (0%) 5/14 (36%) 0/14 (0%) 0/14 (0%) 0/14 (0%) 1/14 (7%) 0/14 (0%) 0/14 (0%)
Total 11/88 (13%) 29/88 (33%) 6/88 (7%) 22/88 (25%) 8/88 (9%) 2/88 (2%) 2/88 (2%) 1/88 (1%) 1/88 (1%) 4/88 (5%)
Av. latency period (days) 188 ± 30 198 ± 31 187 ± 43 180 ± 27 207 ± 20 174 ± 18 153 ± 12 107 146 211 ± 36
Abbreviations: FBL, follicular B cell lymphoma; DLBCL, diffuse large B cell lymphoma; PCT, plasmacytoma; SMZL, splenic marginal zone lymphoma; 
SBL, small B cell lymphoma; PTLL, precursor T cell lymphoblastic lymphoma; STL, small T-cell lymphoma.
# De novo DLBCL refers to Bethesda classification "DLBCL centroblastic"; however, to stress the parallel to human de novo lymphomas we use this 
term.
*In this group one of the 17 mice that developed tumors had two tumors, hence a total number of 18 tumors.Retrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
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The same RT-PCR analyses were performed for NIH 3T3
cells infected with the four viruses, which led to the same
splice pattern (data not shown). In addition, Northern
blot hybridizations with an ecotropic env-probe and with
a probe covering the novel SA'-SD' defined exon in gag
were performed with RNA isolated from these cells (Fig.
5). Besides the expected hybridization patterns of promi-
nent bands of full-length (env and gag probe) and env
mRNA (only env probe) sizes, a weaker band of a size cor-
responding to splice product C (4.4 kb) was detected with
both probes. No distinct band corresponding to spliced
RNA B was observed, suggesting a very low level of pro-
duction and/or significant messenger instability.
Provirus integration site analyses
In order to identify a possible connection between specific
retroviral integration sites (RIS) and specific diagnostic
tumor types, provirus integration sites from the majority
of the induced tumors were isolated and sequenced. We
have then by subsequent homology searches of the mouse
genome databases identified 240 unambiguous integra-
tion sites (Table 3). These integration site sequences rep-
RT-PCR analyses of splice products generated in vivo Figure 4
RT-PCR analyses of splice products generated in vivo. (A) The structures of the potential splice products A to D are illustrated 
at the top, with the positions and orientations of the PCR primers (see Materials and Methods) from the four primer sets 
depicted below. The predicted origins and sizes of the amplified fragments are given at the right. (B) Shown are examples from 
each series of amplified RT-PCR products visualized on ethidium bromide-stained agarose gels. The employed primer sets (#1 
to #4) are listed above the lanes. Size markers are indicated at the left.
SA’-gag SA-env
SD- env SD’-gag
Potential 
splice products
A
B
D
Primer set #
Akv MLV provirus
C
200 bp
400 bp
700 bp
1300 bp
2000 bp
1234
Tumor #11
(PCT)
Tumor #19
(DLBCL)
Akv-wt
1234 1234 1234 1234 1234 12341234
Tumor #13
(SMZL)
Tumor #17
(Hist. sarc)
Akv-CD
Tumor #14
(FBL)
Tumor #15
(de novo DLBCL)
Akv-EH
Tumor #1
(DLBCL)
Tumor #14
(DLBCL)
Akv-CDH
*** *** *** ***
A
B
Primer set #
4 A: ~ 170 bp
1 D: ~ 1900 bp
2 B: ~ 400 bp
3 B or C: ~150 bpRetrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
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resent tumors from 30 out of 40 (104 sequences), 14 out
of 19 (46 sequences), 14 out of 18 (51 sequences), and 11
out of 16 (39 sequences) mice infected by Akv-wt, Akv-
CD, Akv-EH, and Akv-CDH, respectively. This corre-
sponds to an average of 3.6 integrations per analyzed
tumor. Based on the searches in the UCSC database [23],
and the Mouse Retrovirus Tagged Cancer Gene Database,
RTCGD [24,25], both version mm8, 111 novel RISs were
identified. In an attempt to pick up candidate cancer genes
that might be associated with specific tumor diagnoses,
we looked for common integration sites (CISs), which
would infer such genes [25,26]. Hence, we compared the
Northern blot hybridizations with an ecotropic specific env probe and a gag probe of RNA isolated from NIH 3T3 cells chron- ically infected with the viruses listed above each lane Figure 5
Northern blot hybridizations with an ecotropic specific env probe and a gag probe of RNA isolated from NIH 3T3 cells chron-
ically infected with the viruses listed above each lane. The sizes of the full-length transcript (unspliced) and the single-spliced env 
transcript are indicated at the left. The arrow indicates splice product C. For verification of integrity and concentration of the 
loaded RNA, the original ethidium bromide stained agarose gel exposing 18S and 28S rRNAs is shown below.
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Table 3: Positions of integrated proviruses in tumor DNA
# Virus Diagnosis Chromosome Position (mm8) Gene/RefSeqa No. of hits in RTCGD (mm8) Novel RISsb Novel CISsc
1 Akv-EH DLBCL (from FBL) 1 24641886 Lmbrd1 0 1 -
2 Akv-EH DLBCL (from FBL) 1 36406157 Cnnm4 0 1 -
3 Akv wt DLBCL (from FBL) 1 78743292 Kcne4 0 1 -
4 Akv-EH PCT 1 82855932 Slc19a3 0 1 -
5 Akv wt FBL 1 93014894 Ramp1 5 - -
6A k v - C D n.d. 1 93022552
7 Akv-EH Lymphoma, NOS 1 120226476 AK080782 0 1 -
8 Akv-CD DLBCL (from FBL) 1 130341056 Cxcr4 3 - -
9 Akv wt PCT 1 135878316 Fmod/Btg2 8 - -
10 Akv wt DLBCL (from FBL) 1 135882183
11 Akv-CD Abscess 1 139604557 --- 1 - 1
12 Akv wt PCT 1 144940508 --- 0 1 -
13 Akv wt PCT 1 163725782 AK029097 0 1 -
14 Akv wt FBL 1 173476364 Slamf7 0 1 -
15 Akv wt PCT 1 174350588 Tagln2/AK006449 2 - -
16 Akv wt DLBCL (from FBL) 1 182219328 MGC68323/AK038867 2 - -
17 Akv-CD SMZL 2 11542293 Il2ra 4 - -
18 Akv-CDH DLBCL (from FBL) 2 13133178 Rsu1 0 1 -
19 Akv-CDH PCT 2 35270244 Ggta1 5 - -
20 Akv wt DLBCL (from FBL) 2 44741201 Gtdc1 0 1 -
21 Akv wt DLBCL (from FBL) 2 46263959 --- 0 1 -
22 Akv wt DLBCL (from FBL) 2 71667822 Itga6/Pdk1 0 1 -
23 Akv wt DLBCL (from FBL) 2 90883313 Slc39a13/Sfpi1 6 - -
24 Akv wt SMZL 2 90883476
25 Akv wt PCT 2 102668507 Cd44 0 1 -
26 Akv wt DLBCL (from FBL) 2 102782324 Pdhx 0 1 -
27 Akv wt FBL 2 118352393 Pak6 0 1 -
28 Akv wt FBL 2 119028536 Spint1 0 1 -
29 Akv-CDH Lymphoma, NOS 2 120301032 Zfp106 1 - 1*
30 Akv-CDH PTLL 2 128875013 Slc20a1 0 1 -
31 Akv-CDH Lymphoma, NOS 2 129283153 Ptpns1 1 - 1
32 Akv-EH PCT 2 131711284 Rassf2 0 1 -
33 Akv-CDH DLBCL (from FBL) 2 158379688 Ppp1r16b 4 - -
34 Akv wt SMZL 2 164051325 Slpi 0 1 -
35 Akv wt DLBCL (from FBL) 2 169860192 Zfp217 5 - -
36 Akv wt FBL 3 22265638 Tbl1xr1 0 1 -
37 Akv-CDH PCT 3 27464311 Aadacl1 0 1 -
38 Akv-CDH DLBCL (from FBL) 3 30203814 Evi1 5 - -
39 Akv-CDH PCT 3 30203870
40 Akv-CDH Lymphoma, NOS 3 76043446 Golph4 0 1 -
41 Akv-EH DLBCL (from FBL) 3 79339620 --- 0 1 -
42 Akv wt FBL 3 90334704 Slc39a1 0 1 -
43 Akv-CD DLBCL (from FBL) 3 96900321 Cd160 0 1 -
44 Akv wt SMZL 3 98031475 LOC433632 13 - -R
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45 Akv-EH PCT 3 98041399
46 Akv-CD SMZL 3 98043109
47 Akv-CDH DLBCL (from FBL) 3 98043150
48 Akv wt PCT 3 98043377
49 Akv wt DLBCL (from FBL) 3 98043659
50 Akv-CD SMZL 3 98064421
51 Akv-CDH DLBCL (from FBL) 3 98127957 Notch2 8 - -
52 Akv-EH PCT 3 108214198 Ampd2 0 1 -
53 Akv-CD SMZL 3 115828351 Dph5 1 - 1
54 Akv wt DLBCL (from FBL) 3 131582947 Papss1 1 - -
55 Akv wt SBL 3 145870070 Bcl10 3 - -
56 Akv wt DLBCL (from FBL) 3 146091393 Mcoln2 0 1 -
57 Akv-EH DLBCL (from FBL) 3 157996860 Lrrc40 0 1 -
58 Akv wt SBL 4 8842182 BC034239 1 - 1
59 Akv-CDH PCT 4 11915327 AK132816 0 1 -
60 Akv-CD DLBCL (from FBL) 4 32560128 Bach2 14 - -
61 Akv wt FBL 4 32611866
62 Akv-CD n.d. 4 32619341
63 Akv wt PCT 4 32702311
64 Akv-CD Histiocytic sarcoma 4 44734542 Pax5 4 - -
65 Akv wt SMZL 4 55369934 Rad23b 1 - 1
66 Akv-CDH Plasma cell prolif. 4 57933461 Akap2 0 1 -
67 Akv-CD DLBCL (from FBL) 4 97386196 Nfia/D90173 2 - -
68 Akv-EH DLBCL (from FBL) 4 132220004 Fgr 3 - -
69 Akv wt SMZL 4 134699599 Dscr1l2 0 1 -
70 Akv-CDH PCT 4 138050107 Pla2g2d 0 1 -
71 Akv wt FBL 5 39921672 Hs3st1 0 1 -
72 Akv-CDH Lymphoma, NOS 5 65179064 Tlr1 1 - 1
73 Akv-CD Histiocytic sarcoma 5 75074642 --- 0 1 -
74 Akv-CDH PTLL 5 107966364 Gfi1 78 - -
75 Akv-CDH PCT 5 121838640 Aldh2 0 1 -
76 Akv-CDH DLBCL (from FBL) 5 141077075 Gna12 4 - -
77 Akv wt DLBCL (from FBL) 6 29717975 4631427C17Rik 0 1 -
78 Akv-EH de novo DLBCL 6 40821642 BC048599 0 1 -
79 Akv-CDH Lymphoma, NOS 6 40955151 2210010C04Rik 0 1 -
80 Akv-CDH PCT 6 54425558 Scrn1 0 1 -
81 Akv wt FBL 6 72441620 BC100525 2 - -
82 Akv wt PCT 6 84016089 Dysf 0 1 -
83 Akv-CDH Lymphoma, NOS 6 88923549 Gpr175 0 1 -
84 Akv-EH DLBCL (from SMZL) 6 99153396 Foxp1 1 - 1*
85 Akv-CDH Lymphoma, NOS 6 113010477 Thumpd3 1 - 1
86 Akv-CD DLBCL (from FBL) 6 120535110 Cecr5 3 - -
87 Akv-CD Histiocytic sarcoma 6 136905161 Arhgdib 0 1 -
88 Akv-CD PCT 6 145079282 Lrmp 4 - -
89 Akv-CDH Plasma cell prolif. 7 18841894 Apoc4 0 1 -
90 Akv wt FBL 7 24263292 Xrcc1 0 1 -
91 Akv wt PCT 7 28498093 5830482F20Rik 0 1 -
Table 3: Positions of integrated proviruses in tumor DNA (Continued)R
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92 Akv-EH de novo DLBCL 7 28691963 Map4k1 1 - 1
93 Akv-EH PCT 7 29760852 Zfp14 0 1 -
94 Akv-CD Histiocytic sarcoma 7 30746023 Fxyd5 0 1 -
95 Akv wt PCT 7 45003648 Flt3l 0 1 -
96 Akv wt DLBCL (from FBL) 7 66812108 Adamts17 0 1 -
97 Akv wt DLBCL (from FBL) 7 73481277 --- 7 - -
98 Akv-CD SMZL 7 76335733 D430020F16 0 1 -
99 Akv-EH DLBCL (from FBL) 7 79083435 Mfge8 0 1 -
100 Akv-EH PCT 7 80764333 AK034740 0 1 -
101 Akv wt PCT 7 82574727 Eftud1 1 - 1*
102 Akv-EH de novo DLBCL 7 99422958 Arrb1/mmu-mir-326 0 1 -
103 Akv wt SBL 7 113972740 Rras2/Copb1 32 - -
104 Akv-CDH DLBCL (from FBL) 7 121248057 AK043969 0 1 -
105 Akv-EH de novo DLBCL 7 126957227 Cd2bp2 2 - -
106 Akv wt DLBCL (from FBL) 7 132147451 4631426J05Rik 0 1 -
107 Akv-CD DLBCL (from FBL) 7 144741729 Ccnd1 21 - -
108 Akv-CD SMZL 8 8401964 --- 0 1 -
109 Akv-EH DLBCL (from FBL) 8 10980425 --- 4 - -
110 Akv wt FBL 8 35575516 Dctn6 0 1 -
111 Akv wt PCT 8 37098099 --- 0 1 -
112 Akv-CD SMZL 8 74527100 Pgls 3 - -
113 Akv wt DLBCL (from FBL) 8 98522228 Gins3 0 1 -
114 Akv wt SBL 8 112753504 BC027816 0 1 -
115 Akv-EH de novo DLBCL 8 118119184 Wwox 1 - 1
116 Akv-EH Lymphoma, NOS 8 123611854 Irf8 1 - -
117 Akv-EH DLBCL (from FBL) 8 126312417 Tubb3/Mela 1 - 1
118 Akv wt DLBCL (from FBL) 8 126312418
119 Akv wt PCT 9 46235263 --- 0 1 -
120 Akv-CD Abscess 9 86514607 A330041J22Rik 0 1 -
121 Akv-CDH PCT 9 104103363 Acpp 1 - 1
122 Akv-EH FBL 9 115327386 --- 0 1 -
123 Akv wt PCT 9 117143474 Rbms3 0 1 -
124 Akv-EH PCT 10 5056902 Syne1 1 - -
125 Akv wt SBL 10 7626524 Map3k7ip2 1 - 1
126 Akv wt FBL 10 19681745 Map3k5 2 - -
127 Akv wt PCT 10 43100419 Pdss2 0 1 -
128 Akv-EH PCT 10 59295561 Dnajb12 2 - -
129 Akv-CD Histiocytic sarcoma 10 75678805 Prmt2 0 1 -
130 Akv wt FBL 10 77412375 Pfkl 0 1 -
131 Akv wt DLBCL (from FBL) 10 8009951 BC058238 2 - -
132 Akv wt DLBCL (from FBL) 10 84366577 Ric8b 0 1 -
133 Akv-EH de novo DLBCL 10 87574719 BC070476 0 1 -
134 Akv-EH de novo DLBCL 10 92501677 Pctk2 1 - -
135 Akv-CD n.d. 10 123752010 --- 0 1 -
136 Akv-CDH PCT 11 3236433 1500004A08Rik 0 1 -
137 Akv wt PCT 11 5331124 AK133342 0 1 -
138 Akv wt DLBCL (from FBL) 11 23587218 4933435A13Rik 4 - -
Table 3: Positions of integrated proviruses in tumor DNA (Continued)R
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139 Akv-CD DLBCL (from FBL) 11 23587651
140 Akv wt PCT 11 32443618 Stk10 1 - 1
141 Akv wt PCT 11 46693128 Timd4 0 1 -
142 Akv-CD PCT 11 51687729 Phf15 0 1 -
143 Akv-EH de novo DLBCL 11 62648918 Trim16 0 1 -
144 Akv wt PCT 11 67380781 Gas7 0 1 -
145 Akv-EH de novo DLBCL 11 74962635 Smg6 9 - -
146 Akv-EH de novo DLBCL 11 78821537 Ksr1 0 1 -
147 Akv-EH PCT 11 86862765 Gdpd1 0 1 -
148 Akv wt DLBCL (from FBL) 11 95031687 Tac4 0 1 -
149 Akv-EH de novo DLBCL 11 102249514 Grn 0 1 -
150 Akv wt DLBCL (from FBL) 11 102990732 Fmnl1 2 - -
151 Akv wt DLBCL (from FBL) 11 106946907 Nol11 0 1 -
152 Akv-CD Abscess 11 107232889 Pitpnc1 1 - 1
153 Akv-EH PCT 11 116126666 Exoc7 0 1 -
154 Akv-CDH Lymphoma, NOS 11 118058083 Pscd1 1 - 1*
155 Akv-CD SMZL 12 3288080 Rab10 0 1 -
156 Akv wt PCT 12 13172238 Ddx1 0 1 -
157 Akv-CD Abscess 12 56600484 Garnl1 0 1 -
158 Akv-EH de novo DLBCL 12 77286036 Zbtb25 1 - 1
159 Akv wt DLBCL (from FBL) 12 80214408 AK132344 1 - 1
160 Akv wt DLBCL (from FBL) 12 86569587 Batf 2 - -
161 Akv-CD DLBCL (from FBL) 12 113688885 BC004786 5 - -
162 Akv wt PCT 13 24453563 Cmah 1 - 1*
163 Akv-CDH DLBCL (from FBL) 13 28624333 --- 0 1 -
164 Akv wt PCT 13 28727388 --- 3 - -
165 Akv-CDH DLBCL (from FBL) 13 28764182
166 Akv-CDH DLBCL (from FBL) 13 28950798 Sox4 79 - -
167 Akv-CD DLBCL (from FBL) 13 28950905
168 Akv-EH de novo DLBCL 13 28955972
169 Akv wt DLBCL (from FBL) 13 28958981
170 Akv-EH DLBCL (from FBL) 13 30695323 Dusp22 4 - -
171 Akv-CD Histiocytic sarcoma 13 30727958
172 Akv wt PCT 13 31914670 Gmds 1 - 1
173 Akv-CD SMZL 13 36214883 Fars2 0 1 -
174 Akv wt PCT 13 37804150 Rreb1 8 - -
175 Akv-CD Histiocytic sarcoma 13 38701503 Eef1e1 1 - -
176 Akv-CD DLBCL (from FBL) 13 43205444 Gfod1 1 - 1*
177 Akv-CD SMZL 13 63488458 Fancc 4 - -
178 Akv wt DLBCL (from FBL) 13 84050271 Mef2c 11 - -
179 Akv-CDH DLBCL (from FBL) 14 6779744 Dnase1l3 1 - 1
180 Akv-CDH Lymphoma, NOS 14 24439077 Rai17 10 - -
181 Akv-CDH PCT 14 25348097 Slmap 1 - 1
182 Akv-EH Lymphoma, NOS 14 29013598 Cacna1d 0 1 -
183 Akv wt SBL 14 30491074 Btd 0 1 -
184 Akv wt DLBCL (from FBL) 14 59481891 --- 0 1 -
185 Akv wt FBL 14 59637396 AK151394 3 - -
Table 3: Positions of integrated proviruses in tumor DNA (Continued)R
e
t
r
o
v
i
r
o
l
o
g
y
 
2
0
0
7
,
 
4
:
4
6
h
t
t
p
:
/
/
w
w
w
.
r
e
t
r
o
v
i
r
o
l
o
g
y
.
c
o
m
/
c
o
n
t
e
n
t
/
4
/
1
/
4
6
P
a
g
e
 
1
3
 
o
f
 
1
9
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
186 Akv-EH de novo DLBCL 14 63115780 Msra 1 - 1*
187 Akv wt PCT 14 72420139 Sucla2 0 1 -
188 Akv wt SMZL 14 113921088 microRNA cluster 2 - -
189 Akv wt FBL 15 57752356 BC066830 0 1 -
190 Akv-CD SMZL 15 58238320 15Ertd621e 0 1 -
191 Akv wt PCT 15 61240727 --- 0 1 1
192 Akv wt PCT 15 61240729
193 Akv wt FBL 15 73548838 Gpr20/Ptp4a3 6 - -
194 Akv-EH DLBCL (from FBL) 15 79567673 Unc84b 4 - -
195 Akv wt DLBCL (from FBL) 15 79728346 Apobec3 0 1 -
196 Akv-EH Plasma cell prolif. 15 90445122 Cpne8 1 - -
197 Akv wt FBL 16 23906462 Bcl6 5 - -
198 Akv-EH de novo DLBCL 16 24049008 --- 5 - -
199 Akv-CD DLBCL (from FBL) 16 24086635
200 Akv-EH DLBCL (from FBL) 16 24101470
201 Akv-EH Lymphoma, NOS 16 24152772
202 Akv wt FBL 16 24178252
203 Akv wt DLBCL (from FBL) 16 32049420 Lrrc33 3 - -
204 Akv-CD n.d. 16 52388367 Alcam 1 - 1
205 Akv wt PCT 17 6624877 Vil2 3 - -
206 Akv wt PCT 17 11630998 Park2 1 - 1*
207 Akv wt DLBCL (from FBL) 17 36597927 2410137M14Rik 0 1 -
208 Akv wt FBL 17 49537999 2310015N21Rik 1 - 1*
209 Akv-EH DLBCL (from FBL) 17 63705275 Fert2 0 1 -
210 Akv-CD SMZL 17 71389894 Kntc2 0 1 -
211 Akv-CDH PTLL 17 74614066 Birc6 1 - -
212 Akv wt PCT 18 11242422 --- 0 1 -
213 Akv-CD SMZL 18 12368360 Npc1 1 - 1
214 Akv-CD SMZL 18 36016553 Cxxc5 3 - -
215 Akv-CDH DLBCL (from FBL) 18 39790170 --- 0 1 -
216 Akv wt FBL 18 42916219 Ppp2r2b 0 1 -
217 Akv-EH de novo DLBCL 18 60930595 Ii/Cd74 0 1 1
218 Akv-EH DLBCL (from FBL) 18 60930793
219 Akv-CD DLBCL (from FBL) 18 60930833
220 Akv wt PCT 18 60931233
221 Akv-CDH PCT 18 60934151
222 Akv wt DLBCL (from FBL) 18 61103722 Camk2a 0 1 -
223 Akv-EH PCT 18 65601468 Malt1 1 - -
224 Akv wt DLBCL (from FBL) 18 67824697 Ptpn2 0 1 -
225 Akv wt FBL 19 11607493 Ms4a4d 0 1 -
226 Akv wt DLBCL (from FBL) 19 34362400 Fas 2 - -
227 Akv-EH de novo DLBCL 19 37505125 Hhex/Exoc6 44 - -
228 Akv-CD DLBCL (from FBL) 19 37532944
229 Akv-EH de novo DLBCL 19 37537038
230 Akv-CD SMZL 19 37560104
231 Akv-CD Histiocytic sarcoma 19 37560104
232 Akv-EH PCT 19 43474871 Cnnm1 0 1 -
Table 3: Positions of integrated proviruses in tumor DNA (Continued)R
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233 Akv-CDH PCT 19 47583866 Obfc1 0 1 -
234 Akv wt DLBCL (from FBL) 19 47963460 AK014581 0 1 -
235 Akv wt PCT 19 53994934 Shoc2 0 1 -
236 Akv wt FBL 19 55633727 Vti1a 1 - 1*
237 Akv wt FBL X 103293531 P2ry10 0 1 -
238 Akv-CDH Lymphoma, NOS X 109985132 Dach2 1 - 1
239 Akv-EH DLBCL (from FBL) X 129928954 Btk 0 1 -
240 Akv wt DLBCL (from FBL) X 162452646 Tmsb4x 1 - 1
aThe gene (or RefSeq) closest to the integrated provirus is given (UCSC, mouse mm8 assembly). --- indicates that the distance to the closest gene/RefSeq is more than 100 kb.
bFor each insertion, it is indicated, based on RTCGD (mm8), whether a novel RIS has been defined.
cFor each insertion, it is indicated, based on RTCGD (mm8), whether a novel CIS has been defined. The definition follows the recommendations from RTCGD with a window size of 100 kb, 50 kb, 
and 30 kb for CISs with 4 (or more), 3, or 2 insertions, respectively. * indicates an exception from this rule, if two integration sites are found within the same gene/RefSeq.
n.d., not determined.
Table 3: Positions of integrated proviruses in tumor DNA (Continued)
Table 4: Frequency of proviral insertions within defined genomic regions
Virus Upstreama Promoterb 1. intron Internal
intron
Last
intron
Downstreamc Exon Outsided
+-+ - +-+ - + - + - + -
Akv-wt 2/104 2% 7/104 7% 5/104 5% 3/104 3% 9/104 9% 16/104 15% 6/104 6% 17/104 16% 2/104 2% 1/104 1% 5/104 5% 8/104 8% 2/104 2% 1/104 1% 11/104 10%
Akv-CD 3/46 7% 6/46 13% 1/46 2% 0/46 0% 3/46 7% 5/46 11% 2/46 4% 8/46 17% 0/46 0% 0/46 0% 4/46 9% 6/46 13% 1/46 2% 0/46 0% 5/46 11%
Akv-EH 3/51 6% 4/51 8% 1/51 2% 0/51 0% 4/51 8% 6/51 12% 2/51 4% 11/51 22% 2/51 4% 0/51 0% 7/51 14% 1/51 2% 2/51 4% 2/51 4% 6/51 12%
Akv-CDH 1/39 3% 2/39 5% 2/39 5% 3/39 8% 7/39 18% 3/39 8% 3/39 8% 5/39 13% 0/39 0% 1/39 3% 5/39 13% 4/39 10% 0/39 0% 0/39 0% 3/39 8%
Total 9/240 4% 19/240 8% 9/240 4% 6/240 3% 23/240 10% 30/240 13% 13/240 5% 41/240 17% 4/240 2% 2/240 1% 21/240 9% 19/240 8% 5/240 2% 3/240 1% 25/240 10%
a Within 3–100 kb upstream of target gene/RefSeq
b Within 0–3 kb upstream of exon1 of target gene/RefSeq
c Within 100 kb downstream of target gene/RefSeq
d Proviral integrations > 100 kb away from gene/RefSeq
+ or - denotes the orientation of the integrated provirus relative to the target gene/RefSeq.Retrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
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integration sites with each other as well as with previously
defined RISs in RTCGD. In principle, using the recom-
mendations from RTCGD with a window size of 100 kb,
50 kb, and 30 kb for CISs with 4 (or more), 3, or 2 inser-
tions, respectively, we were hereby able to define 35 novel
common integration sites (CISs) (Table 3). Just a single
one of these could be correlated with a specific diagnosis
and with a specific virus, since in two independently Akv-
wt induced plasmacytomas a definite region of chromo-
some 15 was targeted. However, this region does not con-
tain genes/RefSeqs within a 100 kb distance from the
integrated proviruses, so for the present we cannot predict
what – if any – candidate gene(s) that might have been
influenced by the integrated proviruses. For the remaining
34 CISs more than one virus and more than one tumor
diagnosis were implicated, which implies that no straight-
forward association between target gene (and/or causative
virus) and tumor type can be deduced.
In six cases, the same chromosomal locus was targeted
several times. These cases include Bach2  (hit 4 times),
Sox4 (hit 4 times), Hhex (hit 5 times), Ii (hit 5 times), a
region of chr. 16 not containing any genes/RefSeqs within
a distance of 100 kb from the integration sites (hit 5
times), and LOC433632 (hit 7 times). Five of these inte-
gration sites were already registered in RTCGD, only the Ii
locus define a completely novel RIS/CIS. This latter find-
ing may suggest that Ii targeting is strongly associated with
the applied model system (virus/mouse strain)[27]. We
also note that an integration has taken place within the
first intron of Stk10 in a plasmacytoma induced by Akv-wt
(Table 3, #140), which appears to be in conflict with the
work of Shin et al., 2004 [28] where Stk10 was described
as a SMZL specific candidate gene.
Finally, we examined if specific regions of the targeted
gene/RefSeq have been favored with respect to orientation
and position of the integrated provirus. We have recently
reported of differences between Akv MLV and an enhancer
mutant hereof, Akv1-99, in their patterns of proviral inser-
tions around host transcription units in the induced
tumors [29]. In line with this, it might be envisioned that
destroying the alternative splice sites of the virus could
lead to a different pattern of integration site selection dur-
ing tumorigenesis; e.g. it might be speculated if particular
positions relative to the target gene somehow would facil-
itate gene deregulation dependent on the presence or
absence of intact SA' and/or SD' sites. Accordingly, we
allocated each individual integration site position and ori-
entation to a defined region, i.e. either upstream, within
the promoter, within 1. intron, within last intron, within
all other introns, within exons, or downstream of the tar-
get gene (Table 4). Eleven cases in total were excluded as
they were positioned – almost with the same distance – in
between two target genes, upstream of one and down-
stream of the other. As seen in table 4, no clear differences
with respect to the four viruses were observed, signifying
that mutations of the alternative splice sites do not have
major effect on the ability of the Akv MLV to affect the tar-
get gene/RefSeq from certain positions and/or orienta-
tions. It might be worth to notice that the overall picture
shows that about half of all integrations are found within
introns, and among these there appear to be a tendency
for a provirus orientation opposite to that of the target
gene. In these cases the formation of chimeric RNA species
by promoter insertion and/or splicing would not be pre-
dicted.
Discussion
We have in the B-lymphomagenic Akv MLV identified a
novel exon, which is defined by the alternative splice
acceptor (SA') and the splice donor (SD') sites located in
the capsid encoding region. While previous studies of
Moloney and Friend MLV have demonstrated production
of a 4.4 kb transcript using the same SD' site together with
the canonical env SA site, this is the first report demon-
strating the existence of an alternative SA' site and produc-
tion of a double-spliced transcript during the life cycle of
a replication-competent simple retrovirus. Yet it remains
to be investigated how widespread this competence is. An
alignment between six murine retroviruses shows that the
conserved splice junction dinucleotide AG is present nei-
ther in Cas-Br-E nor in Moloney MLV, although the region
in general is well-conserved (Fig. 6).
We did not perform detailed analyses of the influence of
the splice site mutations on the viral replication. How-
ever, since the same number (105 to 106) of infectious
virus particles, as measured by infectious center assays,
were injected from each virus series, and since the mutant
viruses induced tumors with comparable incidences and
latencies as the wild-type virus, it is not likely that the
mutations had imposed severe weakening on the in vivo
spreading capability. Hence the observed shifts in specifi-
city of the induced tumors most likely are a direct result of
the introduced mutations. However, we note that Houzet
DNA sequence alignment around the Akv MLV SA' site in  the capsid-coding region of a series of different ecotropic  MLVs Figure 6
DNA sequence alignment around the Akv MLV SA' site in 
the capsid-coding region of a series of different ecotropic 
MLVs. The 3' splice acceptor site consensus sequences are 
shown on top, with the border of the novel gag exon indi-
cated by a vertical line. The boldfaced A in the sequence indi-
cates the presumed branch point.
SA’- consensus:       CTRAYY..........................YYYYYYYYNCAG|G
Akv:        TTTTCCTCCTCTGATCTATATAACTGGAAAAATAATAATCCTTCCTTCTCTGAG|GAT
SL3-3:      TTTTCCTCCTCTGATCTATATAACTGGAAAAATAATAATCCTTCCTTCTCTGAG|GAT
Moloney:    TTCTCCTCTTCTGACCTTTACAACTGGAAAAATAATAACCCTTCTTTTTCTGAA|GAT
Friend:     TTTTCCTCCTCTGACCTCTATAACTGGAAAAATAACAACCCCTCTTTCTCCGAG|GAC
SRS19-6:    TTCTCCTCCTCTGACCTGTATAATTGGAAAAATAACAACCCTTCTTTTTCTGAG|GAT
Cas-Br-E:   TTCTCCTCTTCTGACCTATACAACTGGAAAAATAATAACCCTTCTTTTTCTGAA|GATRetrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
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et al. [19] observed a reduction in titer of SD'-mutants of
Friend virus.
The in vivo significance of the alternative splice sites was
exposed by a change of the oncogenic properties of Akv
MLV, when synonymous mutations destroying the SA'
site, the SD' site, or both sites simultaneously were intro-
duced. First and foremost, the obvious capability of Akv
MLV to induce follicular B cell lymphoma was seriously
weakened, when one or both of the alternative splice sites
were mutated, suggesting that this competence relies on
intact SA' and SD' sites and a proper balance between all
the produced transcripts (one full-length, two single-
spliced, and one double-spliced). The integrity of Akv
MLV seems fundamental for its capability to induce FBL;
thus we just reported that Akv MLVs with mutated
enhancer sequences retained the ability to induce tumors
of B-cell type, but altered specificities were observed,
including an impaired ability of FBL induction [11]
A more complex picture was observed regarding the
strong predisposition of Akv MLV for plasmacytoma
induction. This predisposition was affected significantly
only if the SA' alone was mutated. Thus, if the SD' site was
mutated along with SA', wild-type potential was restored.
This may indicate that the ability to induce plasmacytoma
is dependent on a fine-tuned balance between the alterna-
tive single-spliced and double-spliced transcripts. If no
double-spliced transcript is produced, while the single-
spliced 4.4 kb transcript still is, as is the case for the SA'
mutant, the single-spliced transcript somehow seems to
be related with a barrier for plasmacytoma induction. On
the other hand, if both transcripts are produced (Akv-wt)
or none of them are produced (the SA'/SD' double
mutant) the virus will hold a potential for inducing plas-
macytomas. This is in line with the overall observation
that the most pronounced effects were observed when the
SA' or SD' splice sites were mutated individually, while the
outcome of infection with the SA'/SD' double mutant in
essence, except for the capability of FBL induction, was
comparable to that of the wild-type virus. It may thus be
speculated if a delicate balance between the alternatively
single-spliced and double-spliced transcripts is a key
determinant for the shift in oncogenic specificity, as dem-
onstrated by the SA' and SD' splice site Akv mutants.
The most striking shifts in specificity observed were the
increased tendency to stimulate development of splenic
marginal zone lymphoma and the exposure of a novel
ability for inducing histiocytic sarcoma for the SA' site
mutant. Although we have shown that mutation of the SA'
site results in inhibition of generation of the double-
spliced product, we are at this point not able to explain or
point to any detailed mechanisms underlying the
observed changes in specificity. The other remarkable shift
in specificity was detected with the SD' mutant, which was
the only virus capable of inducing centroblastic DLBCL,
i.e. tumors for which an origin from the follicle or mar-
ginal zone could not be inferred and comparable to de
novo  DLBCL in humans. Moreover, since the exposed
potential appeared quite strong (35% of the SD'-mutant
induced tumors fell within this diagnosis), and since such
tumors are in general rare in mice, this mutant virus may
be a helpful starting point tool to create a solid mouse
model of human de novo DLBCL.
Obviously, the proposed significance of proper balances
between the four different transcripts for the observed
shifts in tumor specificity may reflect a need for a well-reg-
ulated balance between resulting translational products.
We did not investigate if novel proteins were produced,
but the open reading frames (ORFs) of both the alterna-
tively singly and doubly spliced transcripts clearly reveal a
potential for additional proteins to be produced. The gene
products of the single-spliced 4.4 kb transcript most prob-
ably correspond to the p50 and p60 proteins made from
the equivalent Friend MLV transcript [19]. These proteins
were produced with translation initiations at two initia-
tion codons (AUGgag and CUGglyco-gag) in the same ORF
and were shown to harbor the N-terminal Gag domain
including matrix, p12, and the first 110 amino acids of the
capsid in frame with the last 116 amino acids of integrase
[19]. Also the smaller double-spliced transcript harbors
smaller ORFs providing a scene for even more MLV pro-
teins.
Intragenic elements such as gag  enhancers have been
known for many years in avian retroviruses [30,31]. How-
ever, it seems unlikely that a similar element is involved
here, since the mutant virus with SA' and SD' sites
mutated together was clearly the less affected one. This
observation, in concert with the observed consequence on
generation of different splice products, more likely sug-
gests that the effect on disease specificity is related to an
RNA processing phenomenon rather than an intragenic
gag determinant with an effect on transcription.
Lymphoma-induction by non-acute murine retroviruses
is associated with multiple proviral insertions that affect
critical host genes. To achieve such multiple insertions the
superinfection resistance caused by Env-expression must
be by-passed. One possibility could be that reduced Env-
expression caused by mutation of the gag splice sites as
reported here might favor superinfection and thereby
multiple proviral insertions. While we cannot exclude this
possibility, our finding of the same number of sequence
tags for proviral insertions for the wild-type and mutated
viruses gives no immediately support to such a mecha-
nism.Retrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
Page 17 of 19
(page number not for citation purposes)
Retroviral insertional mutagenesis has been established as
a solid strategy for the identification of candidate cancer-
causing genes [6,26,32-34]. Accordingly, in an effort to
relate specific genes or pathways with specific diagnoses,
splice pattern, or causative virus, we identified a pool of
240 integration sites from which 111 novel RISs and 35
novel CISs were defined. Our analyses did not immedi-
ately point to any clear correlations; nevertheless the col-
lection of candidate genes may prove to be a central input
in future attempts to understand the exact roles of the dif-
ferent splice transcripts and/or their resulting transla-
tional products in hematopoietic differentiation and
tumorigenesis.
Conclusion
We have in the B-lymphomagenic Akv MLV in the gag
region identified a novel exon, which represents the first
example of a doubly spliced gammaretroviral transcript.
Mutations of the alternative splice sites that define this
novel transcript change the distribution of the different
induced tumor phenotypes as well as generate tumors of
additional specificities such as de novo diffuse large B cell
lymphoma and histiocytic sarcoma. Provirus integration
site analyses revealing 111 novel RISs and 35 novel CISs
did not clearly point to specific target genes or pathways
to be associated with specific tumor diagnoses or individ-
ual viral mutants. However, the list of potential target
genes will be useful for future studies of hematopoietic
differentiation and tumorigenesis.
Methods
Exon trapping
Exon trapping was performed by using an Exon Trapping
System kit (GibcoBRL) in essence according to supplied
protocol. In brief, Akv DNA was digested with BamHI or
BglII and all restriction fragments were subcloned into the
pSPL3 plasmid, which in addition to sequences necessary
for replication and growth in Escherichia coli contains
SV40 sequences that provide for replication and transcrip-
tion in COS-7 cells, splicing signals, and a multiple clon-
ing site. Following transformation into E. coli, plasmid
DNA was isolated and transfected into COS-7 cells. Total
RNA was isolated from cultured cells and used for first-
strand cDNA synthesis. The cDNA was PCR amplified in
two rounds with primers located in the vector exons. The
outcome of the PCR amplifications was several different
fragments, which were all sequenced. Two of trapped
sequences could be verified as exons by RT-PCR analyses
of RNA isolated from Akv MLV infected cells. The two
trapped exons were defined by the same splice acceptor
site (SA', located in the gag region, Fig. 1), but by different
splice donor sites (SD' and SD*, Fig. 1), and the sizes were
235 bp and 180 bp, respectively.
Generation of viruses
The mutations of Akv MLV at splice acceptor (SA') and/or
splice donor site (SD') sites were introduced by PCR-based
oligonucleotide directed mutagenesis using the following
primers harboring the wanted mutations (underlined):
Mut-C: 5'-CTATATAACTGGAAAAATAATAATCCATCAT-
TCAGTGAAGATCCAGGTAAACT-3', Mut-D: 5'-
GGATTATTATTTTTCCAGTTATATAGATCGCTGGAG-
GAAAACG-3', and Mut-H: 5'-TTGGGATTACACCAC-
CCAAAGGGGACGAAACCACCT-3'. A 720 bp Bsu36I –
Bsu36I fragment harboring the mutations was cloned into
the full length parental provirus. The correct sequence of
the introduced Bsu 36I fragment was verified by sequence
analysis.
Pathogenicity experiments
Akv wild-type virus λ623 and the three different alterna-
tive splice site mutant viruses, Akv-CD, Akv-EH, and Akv-
CDH, mutated in either the SA' or SD' site, or in both sites
simultaneously, were injected into newborn mice of the
inbred NMRI strain, as described in details [35]. Control
mice of the same colony were mock injected with 0.1 mL
complete medium. The animals were monitored 5 days
per week. Mice were sacrificed and autopsied when show-
ing signs of illness or tumor development. Tumor devel-
opment was diagnosed on the basis of grossly enlarged
lymphoid organs after having reached the size described
earlier, which is compatible with lymphoma [36]. Lym-
phoid tumor tissues and the liver were dissected, stored
frozen (-80°C) and/or fixed in formalin for further analy-
sis. Statistical analysis was carried out using the two-tailed
Fisher's exact test.
Histopathological examination and immunohistochemical 
analysis
Formalin-fixed, paraffin-embedded sections from lymph
nodes, thymus, spleen and liver were analyzed. Three-to-
five micrometer-thick sections were cut and stained with
hematoxylin and eosin (H&E), and when indicated with
Giemsa, PAS or chloroacetate esterase. Tumors were clas-
sified according to the Bethesda proposals for classifica-
tion of murine hematopoietic neoplasms [22,37].
Immunohistochemistry was performed on an automated
immunostainer (Ventana Medical System, Inc.; AZ, USA),
according to the protocol provided by the company with
minor modifications. After deparaffinization and rehydra-
tion, the slides were placed in a microwave pressure
cooker in 0.01 M citrate buffer (pH 6.0), containing 0.1%
Tween-20 and heated in a microwave oven at maximum
power for 30 min. After cooling in Tris-buffered saline, the
sections were incubated with 3% goat or rabbit serum for
20 min. The antibody panel used included CD3,
CD79acy, TdT, myeloperoxidase (Dako, Hamburg, Ger-
many), B220/CD45R and MAC3 (BD Pharmingen, NJ,Retrovirology 2007, 4:46 http://www.retrovirology.com/content/4/1/46
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USA). Appropriate positive controls were used to confirm
the adequacy of the staining.
Northern blot analysis
Total cellular RNA was extracted from chronically infected
NIH 3T3 cells by Trizol Reagent (Invitrogen), following
the manufacturer's recommendations. Approximately 25
μg of RNA from each series (Akv-wt, Akv-CD, Akv-EH,
Akv-CDH, and mock-infected cells) was size-fractionated
on a 1.2% formaldehyde/agarose gel, and transferred to a
nylon filter membrane (Zeta-Probe GT; Bio-Rad) under
alkaline conditions (50 mM NaOH). Prehybridzation,
hybridization, and washing procedures were according to
standard protocol described in the instruction manual
from Zeta-Probe GT [(pre)hybridization buffer: 0.25 M
sodium phosphate, pH 7.2, 7% SDS, and washing buffers:
20 mM sodium phosphate, ph 7.2, 5% (1%) SDS). The
hybridization probes were a 32P random priming labeled
envelope specific probe (a 330 bp SmaI fragment of Akv
MLV (positions 6240to 6570) [38]]) and a 32P random
priming labeled gag  specific probe covering the novel
exon. The gag probe was a 380 bp PCR-fragment ampli-
fied by the following primers: gag-forward: 5'-ATGGT-
CAGTTGCAGTACTGGCCGT-3' and gag-reverse: 5'-
TGGGGCTTCGGCCCGCGTTTTGGA-3'. The integrity and
concentration of the RNA were confirmed by visual
inspection of ethidium bromide-stained 18S and 28S
rRNAs.
PCR and RT-PCR analyses
Genomic DNA was purified from frozen tumor tissues by
DNeasy Tissue Kit (Qiagen). Conservation of the intro-
duced mutations was examined by PCR amplifying the
region enclosing the mutations and by using the primers
depicted in Fig. 1 (primer sequences and positions in Akv
provirus: Forward primer, 5'-CCTATGAACCCCCTCCGT-
GGGTCA-3', nucleotides 1387–1410, and Reverse primer,
5'-TATTAAAGATCCTTTCGGCTTC-3', nucleotides 2412–
2390). The resulting PCR products were analyzed by aga-
rose gel electrophoresis, purified, and sequenced with
nested sequencing primers (numberings refer to positions
in Akv provirus). Forward primer, 5'-CGGGGAGGA-
GAAGCAGCGGGTGCT-3', nucleotides 1952–1976, and
Reverse primer, 5'-GTCCCTAATAATTGCTGGCAAT-3',
nucleotides 1942-1921.
For the RT-PCR analyses, total cellular RNA was extracted
from tumor tissues or chronically infected NIH 3T3 cells
by Trizol Reagent (Invitrogen), following the manufac-
turer's recommendations. 1–5 μg total RNA was used to
make first-strand cDNA by First-Strand cDNA Synthesis
Kit (Amersham Biosciences) with an oligo-dT primer. This
was followed by standard PCR amplification using four
different primer sets, #1 to #4. Primer set #1: Forward
primer, 5'-CCGACCCACCGTCGGGAGGAT-3', and
reverse primer, 5'-CCTCATCAAACAGGGTGGGACT-3'.
Primer set #2: Forward primer, 5'-CCGACCCACCGTCG-
GGAGGAT-3', and reverse primer, 5'-CACCCACACG-
GAGTCTCCAAT-3'. Primer set #3: Forward primer, 5'-
GATTACACCACCCAAAGAGCTC-3', and reverse primer,
5'-CACCCACACGGAGTCTCCAAT-3'. Primer set #4 (env
transcript): Forward primer, 5'-TTGGAGAC-
CCCCGCCCAGGGACCACC-3', and reverse primer, 5'-
CACCCACACGGAGTCTCCAAT-3'. The resulting RT-PCR
products were analyzed by agarose gel electrophoresis,
and in most cases purified and sequenced.
Provirus tagging and analyses
Genomic DNA isolated from the induced tumors was ana-
lyzed for provirus integration sites by a splinkerette-based
PCR method [26], described in details in [39]. The result-
ing host/virus junction fragments were sequenced, and
the cellular flanking sequences were compared (BLAT
search) to the UCSC Genome Browser, version mm8, to
determine the chromosomal position of the integrated
provirus. To identify possible novel retrovirus integration
sites (RISs) and common integration sites (CISs), the indi-
vidual integration sites were concomitantly matched up to
the Retroviral Tagged Cancer Gene Database (RTCGD),
version mm8 [24,25]. The definition of a CIS follows the
recommendations from RTCGD with a window size of
100 kb, 50 kb, and 30 kb for CISs with 4 (or more), 3, or
2 insertions, respectively. Exception from the recom-
mended window sizes was allowed in a few cases when
two (or more) integrations were found within the same
gene/RefSeq (Table 3).
DNA sequencing analysis
Amplified PCR products or purified plasmid preparations
were sequenced with the DYEnamic ET terminator cycle
sequencing kit (Amersham Pharmacia Biotech), following
the manufacturer's recommendations, and reaction prod-
ucts were analyzed on an automated DNA sequencer
(Applied Biosystems Inc.).
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